Posted inWire
Royalty Pharma acquires Nuvalent cancer drug royalties in $315 million deal
NEW YORK - Royalty Pharma plc said on Tuesday it acquired a royalty interest in two of Nuvalent Inc's experimental lung cancer therapies for up to $315 million, betting on…